The news highlights Viking Therapeutics' progress in its obesity-drug program, which is a positive development. The consideration of manufacturing partnerships suggests a strategic move to scale up production, potentially leading to increased revenues and market presence. This is likely to have a positive short-term impact on VKTX's stock price.